LAU-DP-12

LAU-DP-12 is a developmental-stage drug candidate being developed by Vectans Pharma for the treatment of acute oral pain. It utilizes the proprietary Lauriad technology, which is a mucoadhesive buccal tablet (MBT) formulation. This technology is designed to adhere to the oral mucosa (typically the gum) and provide a sustained release of the active pharmaceutical ingredient (API) over a period of 12 to 16 hours. By delivering the drug directly to the site of the condition, the Lauriad platform aims to achieve high local concentrations of the medication while minimizing systemic exposure and associated side effects. LAU-DP-12 is categorized within Vectans Pharma's supportive care pipeline and is currently in the preclinical or early development phase.